Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial save search
Rockwell Medical Submits Supplemental Data to FDA for IND Application for Phase 2 FPC Home Infusion Trial
Published: 2022-05-12 (Crawled : 13:00) - biospace.com/
RMTI | $1.49 -2.61% -4.08% 0
|
Health Technology
|
| O: 1157.14%
H: 2.03%
C: -32.56%
fda application trial home phase 2
Vistagen Announces Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder
Published: 2023-08-07 (Crawled : 14:00) - biospace.com/
VTGN | $4.64 -1.7% 38K
|
Health Technology
|
| O: 1090.48%
H: 0.0%
C: 0.0%
ph94 positive spray trial results
Evofem Presents Data Detailing Fewer Urinary Tract Infections in Women Using Phexxi in the Phase 3 AMPOWER Clinical Trial
Published: 2022-05-06 (Crawled : 13:00) - prnewswire.com
EVFM | $0.0149 740K
|
Health Technology
|
| O: 876.43%
H: 0.0%
C: 0.0%
women phexxi infections trial phase 3
Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)
Published: 2023-09-28 (Crawled : 10:00) - globenewswire.com
BNOX | $0.9469 2.57% -4.33% 130
|
n/a
|
| O: 480.71%
H: 12.06%
C: -41.08%
bnc210 positive topline trial results
Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers
Published: 2024-02-20 (Crawled : 13:00) - globenewswire.com
MNPR | $0.657 1.08% -3.17% 31
|
Health Technology
|
| O: 317.4%
H: 9.09%
C: -53.22%
mnpr-101 clearance trial advanced
Xenetic Biosciences, Inc. Announces Positive Data from Partner’s Pivotal Phase 3 Clinical Trial Utilizing PolyXen(R) Platform Technology
Published: 2020-12-09 (Crawled : 17:00) - biospace.com/
XBIO | $3.78 200
|
Health Technology
|
| O: 258.33%
H: 51.16%
C: -18.09%
positive phase 3 trial
EyePoint Pharmaceuticals Announces Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet AMD Achieving All Primary and Secondary Endpoints
Published: 2023-12-04 (Crawled : 12:00) - globenewswire.com
EYPT | News | $15.53 -5.71% 60K
|
Health Technology
|
| O: 232.83%
H: 2.0%
C: -16.64%
eyp-1901 positive pharmaceuticals topline trial
Madrigal Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis
Published: 2022-12-19 (Crawled : 13:00) - biospace.com/
MDGL | $204.65 -6.29% -6.78% 350
|
Health Technology
|
| O: 219.37%
H: 0.0%
C: 0.0%
treatment fibrosis liver topline trial positive nash
Clinical Trial Approval For The Company's Novel Adjuvanted Recombinant Shingles Vaccine REC610 In The Philippines Jiangsu Recbio Technology Co., Ltd. is pleased to announce that, the Group has recently...
Published: 2022-12-19 (Crawled : 07:00) - biospace.com/
MDGL | $204.65 -6.29% -6.78% 350
|
Health Technology
|
| O: 219.37%
H: 0.0%
C: 0.0%
rec610 vaccine technology trial approval group
Merrimack Provides Ipsen Report That Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Published: 2022-11-09 (Crawled : 15:00) - biospace.com/
MACK 4 | $14.71 -0.14% -0.07% 560
|
Health Technology
|
| O: 215.75%
H: 8.16%
C: -0.95%
onivyde report pancreatic
Jasper Therapeutics Announces Positive Clinical Data from a Phase I/II Trial of Briquilimab as a Conditioning Treatment in Sickle Cell Disease and Beta Thalassemia
Published: 2023-01-03 (Crawled : 14:00) - biospace.com/
JSPR | $22.03 -0.36% -0.14% 5
|
|
| O: 210.62%
H: 153.33%
C: 82.67%
treatment disease trial therapeutics positive
Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)
Published: 2024-01-02 (Crawled : 20:00) - biospace.com/
LBPH | $19.75 -2.57% -2.58% 0
|
Manufacturing
|
| O: 206.47%
H: 39.72%
C: 35.82%
lp352 positive pharmaceuticals topline
SOCMA and Greenland Technologies Sign Co-Operation Agreement to Support U.S. Production of Electric Industrial Vehicles
Published: 2021-02-18 (Crawled : 12:09) - prnewswire.com
GTEC | $1.69 -1.23% 15
|
Producer Manufacturing
|
| O: 193.11%
H: 19.39%
C: -33.39%
trial vehicles
Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in Japan
Published: 2024-02-26 (Crawled : 14:30) - biospace.com/
AKLI | $0.248 3.77% 4.02% 1
|
|
| O: 193.1%
H: 13.69%
C: -30.36%
endeavorrx japan positive adhd trial results
BeyondSpring Announces Positive Topline Results from its DUBLIN-3 Registrational Trial of Plinabulin in Combination with Docetaxel for the Treatment of 2nd/3rd Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Wild Type
Published: 2021-08-04 (Crawled : 12:00) - biospace.com/
BYSI | $2.43 6.11% 6.91% 0
|
Health Technology
|
| O: 191.8%
H: 6.76%
C: -5.41%
treatment lung cancer positive results cancer topline trial plinabulin
Ambrx Announces Encouraging Preliminary Safety and Efficacy Data Evaluating ARX788 in HER2 Positive Metastatic Breast Cancer Patients Who Progressed Following T-DM1 Treatment
Published: 2022-12-09 (Crawled : 14:00) - biospace.com/
AMAM 4 | $28.0 0.0% 1.4M
|
Professional, Scientific, and T...
|
| O: 185.44%
H: 288.03%
C: 288.03%
arx788 treatment breast positive cancer her2- her2 metastatic breast cancer
First Wave BioPharma Reaches Enrollment Target for Phase 2 SPAN Adrulipase Clinical Trial in Cystic Fibrosis
Published: 2023-06-13 (Crawled : 11:00) - globenewswire.com
FWBI | $3.02 -3.21% -2.63% 35
|
Manufacturing
|
| O: 150.48%
H: 4.89%
C: -46.85%
biopharma fibrosis adrulipase trial phase 2
Aclaris Therapeutics Announces Positive Preliminary Topline Data from 12-Week Phase 2a Trial of Oral ATI-450 for Moderate to Severe Rheumatoid Arthritis
Published: 2021-01-19 (Crawled : 12:03) - globenewswire.com
ACRS | $1.185 1.28% 42K
|
Health Technology
|
| O: 138.95%
H: 41.99%
C: 34.02%
positive trial rheumatoid arthritis topline phase 2b
Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder
Published: 2024-04-10 (Crawled : 12:30) - globenewswire.com
ADIL | News | $1.71 0.59% 1.16% 290
|
Health Technology
|
| O: 123.48%
H: 0.0%
C: 0.0%
ad04 alcohol publication treatment pharmaceuticals for trial potential
Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04
Published: 2024-04-10 (Crawled : 14:30) - biospace.com/
ADIL | News | $1.71 0.59% 1.16% 290
|
Health Technology
|
| O: 123.48%
H: 0.0%
C: 0.0%
ad04 publication pharmaceuticals trial
Gainers vs Losers
| 50% | 50% |
Top 10 Gainers
CSSE 4 | $0.299 96.32% 7M
|
Consumer Services
BRFH 4 | $1.99 80.91% 13M
|
Manufacturing
BOF | $1.915 63.68% 620K
|
CDTX | News | $14.57 18.55% 330K
|
Health Technology
ULBI M | $10.12 15.92% 120K
|
Producer Manufacturing
LRHC | $1.79 11.88% 3K
|
n/a
TRU | $74.475 8.44% 100K
|
Technology Services
BQ | $0.279 7.31% 14K
|
Consumer Non-Durables
CASI | $2.61 6.97% 13K
|
Health Technology
CZOO | $11.85 6.76% 1.2M
|
Your saved searches
Save your searches and get alerts when important news are released.